Here's the Deal
 

Baird's Investment Banking Group is pleased to announce the following transaction:

July 2012


TESARO, Inc.
Initial Public Offering
$81.0 Million


Baird served as a co-manager in this transaction


TESARO, Inc. (“TESARO” or the “Company”) (NasdaqGM: TSRO) recently completed an initial public offering of 6,000,000 shares of its common stock at a price of $13.50 per share, generating gross proceeds of approximately $81 million. The Company intends to use the net proceeds from the offering to fund clinical trials, acquire or in-license product candidates and for working capital and general corporate purposes.

TESARO is an oncology-focused biopharmaceutical company focused on acquiring, developing, and commercializing therapeutics and supportive care products to improve the lives of cancer patients. The Company has in-licensed and is currently developing three product candidates; rolapitant, niraparib and TSR-011. TESARO intends to continue to leverage the experience and competencies of the Company’s management team to identify, acquire, develop and commercialize additional pharmaceutical products and product candidates that are safer and more effective than current therapies in the treatment and support of cancer patients. TESARO is based in Waltham, Massachusetts.

For additional information about this transaction, please contact:
Co-Head, Equity Capital Markets
(415) 627-3279
Director
(650) 858-3817

Social Icons

Careers|Help|Site Map|Important Disclosures|Privacy Policy|Financial Information|Business Continuity
©2013 Robert W. Baird & Co. Incorporated.
Global Websites: Europe | Asia
The services featured on this Web site may not be available in all jurisdictions or to all persons/entities. For more information, please see Important Disclosures. Robert W. Baird & Co. Incorporated. Member SIPC.